[Brentuximab vedotin: new treatment for CD30+ lymphomas].

Abstract

Brentuximab vedotin is a new antibody-drug conjugate composed of the anti-CD30 chimeric monoclonal antibody and the potent antimicrotubule drug monomethylauristatin E. In two phase II clinical trials, treatment with single-agent brentuximab vedotin resulted in response rates of 75% in relapsed/refractory Hodgkin lymphoma and 86% in relapsed/refractory systemic anaplastic large-cell lymphoma. Peripheral sensory neuropathy (40%) and neutropenia (20%) were the most frequent side effects, generally mild and manageable. After a large use in a compassionate program, brentuximab vedotin was approved in France in October 2012 for the treatment of Hodgkin lymphoma after failure of autologous stem cell transplantation or after failure of at least two prior multiagent chemotherapy regimens in patients non eligible for autologous transplantation, and for the treatment of systemic anaplastic large-cell lymphoma after failure of at least one prior multiagent chemotherapy regimen.

• Authors: Louis Terriou, Sarah Bonnet, Houria Debarri, Hélène Demarquette, Franck Morschhauser
• Journal: Bulletin du cancer (Bull Cancer) 2013 Jul-Aug Vol. 100 Issue 7-8 Pg. 775-9 ISSN: 1769-6917 [Electronic] France
• Vernacular Title: Brentuximab vedotin: nouvelle option thérapeutique dans la prise en charge des lymphomes CD30+
• PMID: 23831822 (Publication Type: Journal Article, Review)

Chemical References

• Immunoconjugates
• Ki-1 Antigen
• Brentuximab Vedotin

Topics

• Brentuximab Vedotin
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Hodgkin Disease (drug therapy, immunology)
• Humans
• Immunoconjugates (therapeutic use)
• Ki-1 Antigen
• Lymphoma, Large-Cell, Anaplastic (drug therapy, immunology)